Method for inhibiting or reducing dry eye disease by IL-1Ra

Patent metadata

Field	Value
Publication number	US-10105441-B2
Application number	US-29838008-A
Country	US
Kind code	B2
Filing date	Aug 15, 2008
Priority date	Aug 16, 2007
Publication date	Oct 23, 2018
Grant date	Oct 23, 2018

Abstract

The present invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-1 and methods for using this composition to treat inflammatory disease of ocular and adnexal tissues by topical administration. The present invention also discloses devices for delivering this composition to target tissues.

First claim

What is claimed is:

1. A method for inhibiting or reducing dry eye disease in a subject characterized as suffering from dry eye disease, comprising locally administering to an ocular tissue or an ocular adnexal tissue of the subject a composition that inhibits the binding of an inflammatory interleukin-1 (IL-1) cytokine to an IL-1 receptor, wherein said composition consists of a pharmaceutical carrier and a polypeptide consisting of the amino acid sequence of SEQ ID NO: 16; wherein the subject characterized as suffering from dry eye disease is identified by detection of a sign or symptom selected from the group consisting of epithelial overexpression of an inflammatory cytokine, vascular hyperplasia or thickening of eyelid margin, neovascularization of eyelid margin or corneal periphery, increase of leukocytes at an ocular surface, or overexpression of a matrix metalloprotease at an ocular surface; and wherein said method inhibits or reduces the severity of at least one of said signs or symptoms.

2. The method of claim 1 , wherein said dry eye disease comprises infectious blepharitis.

3. The method of claim 1 , wherein said dry eye disease comprises non-infectious blepharitis.

4. The method of claim 1 , wherein said method does not comprise administration of an antibiotic compound.

5. The method of claim, 1 wherein said composition is present in a concentration of 0.1-10% (mg/ml).

6. The method of claim 1 , wherein the form of said composition is in a form of a solid, a paste, an ointment, a gel, a liquid, an aerosol, a mist, a polymer, a film, an emulsion, or a suspension.

7. The method of claim 1 , wherein said composition is administered topically.

8. The method of claim 1 , wherein said method does not comprise systemic administration or substantial dissemination to non-ocular tissue.

9. The method of claim 1 , wherein said pharmaceutical carrier is selected from the group consisting of a physiological acceptable salt, poloxamer analogs with carbopol, carbopol/HPMC, carbopol-methyl cellulose, carboxymethylcellulose (CMC), hyaluronic acid, cyclodextrin, and petroleum.

10. The method of claim 1 , wherein said dry eye disease is associated with posterior blepharitis or meibomian gland dysfunction.

11. The method of claim 1 , wherein said dry eye disease comprises aqueous deficiency dry eye or evaporative dry eye.

12. The method of claim 1 , wherein said pharmaceutical carrier is an aqueous carrier.

Assignees

• Dana Reza
• Dastjerdi Mohammad
• Schepens Eye Res Inst

Inventors

• Dana Reza
• Dastjerdi Mohammad

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K36/537

  Salvia (sage) · CPC title

• A61K31/7105

  Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title

• A61K38/21

  Interferons {[IFN]} · CPC title

• A61K36/258

  Panax (ginseng) · CPC title